Alnylam Pharmaceuticals, Inc. ALNY, a leading RNAi therapeutics
company, today announced that it has commenced an underwritten public offering
of shares of its common stock to raise aggregate proceeds of approximately
$125 million. All of the shares in the offering are to be sold by Alnylam.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in